Patients with rheumatoid arthritis derive benefit from treatment with D-penicillamine (Multicentre Trial Group, 1973; Huskisson, 1976a) . This improvement takes some months to occur and is accompanied by a fall in the erythrocyte sedimentation rate (ESR) and rheumatoid factor titre, and improvement in the systemic features of the disease. These actions distinguish D-penicillamnine from the anti-inflammatory drugs and suggest a more fundamental mode of action (Huskisson, 1976b) . Serious complications of therapy sometimes occur and may affect a number of tissues. They include rashes, mouth ulcers, thrombocytopenia, leucopenia, bone marrow aplasia, and nephropathy, and they may occur separately or in combination. In addition there have been isolated case reports of a lupus-like syndrome developing in patients taking D-penicillamine (Harpey et al., 1971; Camus et al., 1974) .
The presence and nature of circulating immune complexes in patients with rheumatoid arthritis has been investigated by several workers (Onyewotu et al., 1974; Roberts-Thomson et al., 1976) , and the effects of D-penicillamine on these complexes have also been studied (Mohammed et al., 1976) . Alteration in the nature of the complexes has been found, and there is also evidence that nephropathy induced by the drug is due to immune complex deposition (Jaffe et al., 1968; Bacon et al., 1976 In the second study 4 patients who developed systemic lupus erythematosus while receiving penicillamine were documented and had skin biopsies for immunofluorescence.
17 patients with penicillamine-induced nephropathy represent a third study, and the changes in serum immunoglobulins in 20 patients treated for 6 months with penicillamine a fourth.
Results
The results of the skin biopsies in the 3 groups of patients in the first study are shown in Table 3 . There was a fall in the titre of rheumatoid factor, immunoglobulin, and complement levels, but no significant change in ANF titre. To isolated reports of a lupus-like syndrome occurring in patients on D-penicillamine (Harpey et al., 1971; Camus et al., 1974 ) the present study adds 4 further cases. In 3 of these patients DNA binding was abnormally high, which is unusual in most other drug-induced lupus syndromes (Hughes, 1973) . The clinical features were typical of SLE, and the patients quickly recovered when the drug was discontinued. Three of these 4 patients also had positive immunofluorescence on skin biopsy.
The nephropathy of D-penicillamine is thought to be due to immune complex deposition (Jaffe et al., 1968; Bacon et al., 1976) . Our studies lend support to this view, a new finding being that the proteinuria will subside in spite of continued therapy. This would also be compatible with an immune complex phenomenon.
The serological findings show that treatment with D-penicillamine is associated with a decrease in latex titre and immunoglobulin levels, including IgA, which did not alter in other studies (Bluestone and Goldberg, 1973) . Complement levels were also significantly affected, though they did not fall below the lower limit of normal. The reasons for these changes are unknown but would again be compatible with the deposition of complexes in tissue including the skin.
These findings suggest that immunoglobulin deposits may occur in the skin and other tissues of patients taking D-penicillamine, and that this deposition may correlate to some extent with the occurrence of tissue reactions.
In addition to the nephropathy other side effects of D-penicillamine, including rashes and the lupus syndrome, could be related to immune complex deposition. The lupus-like syndrome could reflect the extreme end of the spectrum of toxic reactions to the drug associated with the disappearance of immunoglobulin and complement from the serum and the appearance of complexes in target tissues. complex deposition. 
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